Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer.

摘要: // Anna Karlsson 1 , Hans Brunnstrom 2, 3 Kajsa Ericson Lindquist Karin Jirstrom Mats Jonsson Frida Rosengren Christel Reutersward Helena Cirenajwis Ake Borg 1, 6 Per 4 Maria Planck 5 Goran Johan Staaf Division of Oncology and Pathology, Department Clinical Sciences Lund, Lund University, Medicon Village, SE 22381 Sweden 2 22185 Regional Laboratories Region Skane, Thoracic Surgery, Skane University Hospital, Oncology, Create Health Strategic Center for Translational Cancer Research, Correspondence to: Staaf, e-mail: johan.staaf@med.lu.se Keywords: large cell lung cancer, LCNEC, mutation, gene fusion, ALK Received: March 01, 2015      Accepted: June 05, Published: 17, 2015 ABSTRACT Large carcinoma with or without neuroendocrine features (LCNEC LC, respectively) constitutes 3–9% non-small cancer but is poorly characterized at the molecular level. Herein we analyzed 41 LC 32 LCNEC (including 15 previously reported cases) tumors using massive parallel sequencing mutations in 26 cancer-related genes fusions RET ROS1 . patients were additionally subdivided into three immunohistochemistry groups based on positive expression TTF-1/Napsin A (adenocarcinoma-like, n = 24; 59%), CK5/P40 (squamous-like, 5; 12%), no marker (marker-negative, 12; 29%). Most common alterations TP53 (83%), KRAS (22%), MET (12%) LCs, (88%), STK11 (16%), PTEN (13%) LCNECs. In general, LCs showed more oncogene compared to Immunomarker stratification revealed 63% adenocarcinoma-like cases, only 17% marker-negative cases. Moreover, associated inferior overall survival ( p 0.007). No detected Together, our analyses support that follow different tumorigenic paths may be stratified subgroups potential implications diagnosis, prognostics, therapy decisions.